Excessive inflammation in sepsis causes microvascular thrombosis and thrombocytopenia associated with organ dysfunction and high mortality. The present studies aimed to investigate whether inhibition of dipeptidyl peptidase-4 (DPP-4) and supplementation with glucagon-like peptide-1 (GLP-1) receptor agonists improved endotoxaemia-associated microvascular thrombosis via immunomodulatory effects.
Introduction
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is released in response to food uptake (Wang et al., 1995) . Under physiological conditions, endogenous GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Activation of GLP-1 receptor signalling improves glucose metabolism via increased insulin release and reduced glucagon secretion of the pancreas in a cAMP/PKA-dependent manner (Gromada et al., 1997) but also exerts pleiotropic effects via other pathways (Pabreja et al., 2014) . Supplementation with GLP-1 receptor agonists or treatment with DPP-4 inhibitors is used to improve glycaemic control (Sturis et al., 2003; Moritoh et al., 2009) , but pleiotropic cardioprotective effects were also observed in experimental studies (Apaijai et al., 2013) . There is also a growing body of evidence for antiinflammatory and anti-atherosclerotic effects of GLP-1 receptor agonists and DPP-4 inhibitors (Shah et al., 2011; Matsubara et al., 2012) . These anti-inflammatory effects were recently confirmed in a model of experimental sepsis (Ku et al., 2010; Kroller-Schon et al., 2012) . Further, Gupta et al. (2012 demonstrated anti-aggregatory effects of the DPP-4 inhibitor sitagliptin on human platelets without providing the mechanism underlying this phenomenon. In a recent publication, Cameron-Vendrig et al. (2016) provided evidence for platelet inhibition by the GLP-1 receptor agonist exenatide leading to reduced thrombus formation in an animal model. The authors also showed that the antiaggregatory and anti-thrombotic effects of exenatide were associated with increased levels of cAMP.
Sepsis is a clinical syndrome characterized by, and secondary to, an excessive immune response to an infection. Subsequent hypotension, coagulopathy and multiple organ dysfunction syndrome are major characteristics of septic shock. An average mortality of 40% makes it a leading cause of death in the Western societies (Levy et al., 2012) . Because of antibiotic resistance and an ageing population, the incidence of sepsis has increased and new therapeutic strategies are urgently needed.
The endotoxin LPS from Gram-negative bacteria triggers inflammation by binding directly via CD14 on monocytes and to endothelial cells via toll-like receptors after forming a complex with LPS binding protein (Anas et al., 2010) . As a consequence, monocytes and vascular endothelial cells express the cell surface protein, tissue factor (TF), subsequently promoting thrombin and fibrin generation (Levi and Ten Cate, 1999; Schouten et al., 2008) . Under conditions of sepsis, massive thrombin generation leads to uncontrolled platelet activation and finally to microvascular thrombosis, clotted capillaries and impaired perfusion of end organs. This clinical syndrome is known as disseminated intravascular coagulation (DIC) and includes both pro-coagulant thrombus formation and haemorrhage caused by consumption of clotting factors (Levi and van der Poll, 2010) .
Recently, we demonstrated that DPP-4 inhibition by linagliptin and treatment with the GLP-1 receptor agonist liraglutide improved survival in endotoxaemic rodents (Steven et al., 2015a) . However, the relevance of GLP-1 receptor signalling to these beneficial effects of DPP-4 inhibition remains unclear. In the present study, we showed that enhanced GLP-1 receptor signalling reduced microvascular thrombosis in a mouse model of endotoxaemia by inhibiting vascular inflammation and by direct cAMP/PKA-dependent inhibition of platelet aggregation. The importance of GLP-1 receptor signalling in mediating these phenomena was further substantiated by using mice with genetic deletion of this receptor À/À mice).
Methods

Animals and in vivo treatment
All animal care and experimental procedures were in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the US National Institutes of Health, and approved by the Ethics Committee of the University Hospital Mainz and the Landesuntersuchungsamt Koblenz (#23 177-07/G 14-1-039). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Alexander et al., 2015a,b,c,d ).
Tables of Links
In these experiments we used C57BL/6J mice, as the wild-type strain, with DPP-4 knockout (DPP-4 À/À ) and GLP-1 receptor knockout (GLP-1r À/À ) on the C57BL/6J background.
All mice were male, and were 10-12 weeks old and weighed 25-30g, at the time of the experiment. DPP-4 À/À mice were kindly provided by Dirk Reinhold (Otto-von-GuerickeUniversity Magdeburg, Magdeburg, Germany) and generated by Didier Marguet (Centre d'Immunologie de MarseilleLuminy, Marseille, France) (Marguet et al., 2000) . GLP-1r
À/À mice were obtained from Charles River (Sulzfeld, Germany) and generated by Daniel Drucker (Mt. Sinai Hospital, Toronto, Canada) (Scrocchi et al., 1996) . Reduced DPP-4 activity in DPP-4 À/À mice was confirmed by DPP-4 activity measurement (Supporting Information Fig. S1A Finally, 72 h after starting treatment, mice were killed by exsanguination during isoflurane anaesthesia, and the blood, aorta, lung and heart tissues were collected. Survival studies were carried out after a single injection of LPS (17.5 mg·kg À1 ; a lethal dose), and drugs were injected 6 h after LPS, at the same concentration as defined above. Survival was monitored for 60 h.
Quantification of nitrosylated haemoglobin in whole blood by EPR
Electron paramagnetic resonance spectroscopy (EPR)-based detection of nitrosyl-iron haemoglobin (HbNO) was used to assess NO production by inducible NOS (iNOS). Samples of venous blood for HbNO/EPR studies were obtained by puncture of the right heart of anesthetized mice and blood samples were immediately frozen and stored in liquid nitrogen, as described before (Steven et al., 2015a) .
Cell culture
The human monocyte cell line (MonoMac-1) (ZieglerHeitbrock et al., 1988) Chemiluminescence-based detection of oxidative burst of monocytes
The oxidative burst mainly reflects NADPH oxidase (Nox) and myeloperoxidase activities and was therefore used as a marker of the degree of activation of cultured monocytes (Daiber et al., 2004a 
Real-time qRT-PCR)
mRNA expression was analysed with real-time qRT-PCR as previously described (Hausding et al., 2013 Platelet count, fluorescence imaging of pulmonary microvascular thrombosis and LDH activity
Pulmonary microvascular thrombus formation in mouse lung was quantified by fluorescence imaging (IVIS Spectrum; PerkinElmer, Waltham, MA, USA) using fluorescent beads (2.5 μM), according to Tokalov and Bachiller (2012. The fluorescent beads were diluted in sterile saline (2 × 10 5 beads per μL; 50 μL per animal) and injected into the tail vein of the animals (3 h after LPS injection). Lungs were removed from the animals, and fluorescence was detected (excitation: λ640 nm emission: λ680 nm). Increased fluorescence signal was taken to show occlusion of microvessels, with fluorescent beads trapped in the embolized vessels. An automated haematology analyser (Sysmex KX-21N) was used to determine the number of thrombocytes in whole blood. Lactate dehydrogenase (LDH) activity was analysed as an indicator of organ damage, in the Department for Clinical Chemistry, University Medical Centre (Mainz, Germany), using the daily routine facilities for inpatient care (Iba et al., 2009 ).
Immunohistochemistry and fluorescence microscopy
For immunohistochemistry, lung segments were fixed in paraformaldehyde (4%), paraffin-embedded and stained with primary antibodies against fibrinogen (Abcam, Cambridge, UK); anti-rabbit biotinylated secondary antibodies were used at dilutions according to the manufacturer's instructions. For immunohistochemical detection, ABC reagent (Vector, Burlingame, CA, USA) and then DAB reagent (peroxidase substrate kit; Vector) as substrates were used. For fluorescence microscopy, lung segments were fixed as described above, and nuclei were stained by DAPI. FBs BJP S Steven et al.
were visualized by excitation on their specific wavelength (excitation: λ640 nm emission: λ680 nm).
Platelet isolation, incubation for Western blot, dot blot and cAMP ELISA All human samples were obtained and handled in accordance with the Declaration of Helsinki and our institutional ethical guidelines. Citrated whole blood was obtained from at least four different healthy volunteers by venepuncture or taken from mice by retro-orbital vein puncture, using silanized glass capillaries. PRP was isolated by centrifugation (200× g for 10 min at 22°C, slow deceleration). Murine or human platelets were incubated in PRP for 15 min with exendin-4 (Abcam, Cambridge, UK), prostacyclin (PGI 2 ) (0.2 ng·mL À1 ), PKA inhibitor (1 μM) (Sigma-Aldrich) or solvent at 37°C. Then, platelets were collected by centrifugation (700× g for 10 min at 22°C), supernatant was removed and platelet pellet was resuspended in lysis buffer. Platelet protein was isolated for dot blot and Western blot analysis. For cAMP ELISA, 1 M HCl solution was added to PRP, and ELISA was performed according to the manufacturer's instructions (Cayman, Ann Arbor, MI, USA).
Western blot and dot blot analysis on murine and human platelets
Proteins from murine or human platelets were separated by SDS-PAGE and blotted on nitrocellulose membrane as described before (Daiber et al., 2004b) . A monoclonal antipVASP-Ser 157 antibody (1:100; Calbiochem (now Merck Millipore, Billerica, MA, USA)) was used to detect cAMPdependent phosphorylation, a monoclonal anti-GAPDH (1:1.000; GeneTex, Irvine, CA, USA) or anti-α-actinin (1:1000, Sigma-Aldrich) antibody served as loading control (Schafer et al., 2003) . GLP-1 receptor protein was detected by a polyclonal anti-GLP-1 receptor antibody (1:1.000; NOVUS, Littleton, CO, USA). Detection and quantification were performed by ECL with peroxidase-conjugated anti-mouse (1:10.000; Vector Lab) secondary antibodies. Densitometric quantification of antibody-specific bands was performed with a ChemiLux Imager (CsX-1400M; Intas, Göttingen, Germany) and Gel-Pro Analyser software (Media Cybernetics, Bethesda, MD, USA). Phosphorylation of PKA substrate protein was assessed by dot blot analysis of platelet protein homogenates, which were transferred to a Protran BA85 (0.45 μm) nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) by a Minifold I vacuum dot blot system (Schleicher & Schuell). Each slot was washed with 250 μL PBS, and the membrane was dried for 45 min at 60°C. For detection of phosphorylated PKA substrate, a phospho-Ser/Thr PKA substrate antibody (Cell Signaling, Beverly, MA, USA) was used at a dilution of 1:1.000. Positive dots were detected by ECL after incubation with a peroxidase-coupled secondary antibody (1:10.000; Vector Lab). All incubation and washing steps were performed according to the manufacturer's instructions. Densitometric quantification of the dots was performed as described in the Western blot section.
Measurement of thrombin generation and aggregation in murine and human PRP
PRP was prepared by centrifugation of citrate-anti-coagulated whole blood (mouse: 100 x g for 4 min at 22°C, slow deceleration, human: 200 x g for 10 min at 22°C, slow deceleration), taken from mice by retro-orbital vein puncture using silanized glass capillaries or by venepuncture from healthy human volunteers. Human platelets were incubated for 15 min with exendin-4, liraglutide or solvent (all dilutions of liraglutide were made in buffer with phenol to exclude effects of the stabilizer). Platelet-dependent thrombin generation triggered by TF or thrombin was assessed in PRP by fluorogenic-calibrated automated thrombography in vitro (Tchaikovski et al., 2007; Jurk et al., 2011) . Thrombin-(2.5 U·mL À1 in mouse, 0.2 U·mL À1 in human) and ADP-induced (6 μM in mouse, 1 μM in human) aggregation was measured in diluted PRP supplemented with MgCl 2 (1 mM) and CaCl 2 (2 mM) using light transmission aggregometry (APACT; DiaSys, Flacht, Germany). Gly-Pro-Arg-Pro (GPRP; 5 mM) was added to avoid clot formation (only in mouse PRP).
Isometric tension recordings
Perivascular fat was removed from murine aorta, which was then cut into 4 mm segments. Rings were mounted on force transducers in organ baths, pre-constricted with PGF 2α and concentration-relaxation curves in response to increasing concentrations of ACh were obtained as described (Oelze et al., 2006) .
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Results are expressed as mean ± SEM. Linear regression for correlation of thrombocytopenia and fluorescence was performed using the Pearson correlation coefficient. Two-way ANOVA (with Bonferroni's correction for comparison of multiple means) was used for comparisons of vasodilator potency and efficacy in response to the endothelium-dependent vasodilator ACh. One-way ANOVA (with Bonferroni's correction for comparison of multiple means) was used for comparisons of fluorescence imaging, platelet count, LDH, mRNA expression, HbNO levels, oxidative burst, CAT, cAMP levels, Western blot and dot blot results. Maximal aggregation and inclination were analysed by using Student's t-test. P values < 0.05 were considered as statistically significant. All statistical analyses were performed using GraphPad Prism 6.0d.
Materials
The Bradford reagent was obtained from BioRad (Munich, Germany). The DPP-4 inhibitor linagliptin was a kind gift from Boehringer Ingelheim Pharma GmbH & Co. KG (Biberach an der Riss, Germany). Liraglutide was purchased as an injection pen (6 mg·mL À1 in phenol-containing solution from Victoza/Novo Nordisk, Plainsboro, NJ, USA). Exendin-4 was purchased from Abcam Biochemicals (Cambridge, MA, USA). For induction of endotoxaemia, we used LPS from Salmonella typhosa (#L6386 purified by phenol extraction; Sigma, St. Louis, MO, USA). Three batches of LPS were pooled and homogenized in a mortar and dissolved in saline, and stocks were frozen at À80°C. Upon thawing, the stocks were sonicated. L-012 was purchased from Wako Pure Chemical Industries (Osaka, Japan). The Quanti Tect probe RT-PCR kit was purchased from Qiagen (Hilden, Germany) and TaqMan probes from Applied Biosystems (Darmstadt, Germany). Fluorescent beads (alignment beads; 2.5 μM) were obtained from Molecular Probes (Eugene, OR, USA). All other chemicals were of analytical grade and were obtained from Sigma-Aldrich, Fluka or Merck.
Results DPP-4 inhibition and treatment with GLP-1 receptor agonist reduced myelomonocytic, iNOS-dependent NO formation and monocyte-derived oxidative stress LPS challenge induced a strong increase in iNOS-derived NO formation in whole blood of wild-type mice, which was significantly reduced by linagliptin or liraglutide treatment. A comparable effect was found in endotoxaemic DPP-4 À/À mice ( Figure 1A ) but not in response to therapy with the GLP-1 receptor agonist in endotoxaemic GLP-1r À/À mice ( Figure 1B ).
Suppression of iNOS activity by the DPP-4 inhibitor in GLP1r À/À mice was only marginal ( Figure 1B) . Also, iNOS expression in aortic tissue was strongly increased in endotoxaemic wild-type mice, probably by infiltrated immune cells, and reduced by linagliptin and liraglutide treatment (Supporting Information Fig. S2A ). In earlier studies, the marker of NOS activity (HbNO) was strictly correlated with hypotension in the endotoxaemic mice (Steven et al., 2015a) . Next, we examined the direct effects of the DPP-4 inhibitor or the GLP-1 receptor agonist on cultures of the human monocyte cell line (MonoMac-1 cells) in response to incubation with LPS for 4 h. Incubation of monocytes with linagliptin or liraglutide dose-dependently reduced the formation of ROS, induced by zymosan A ( Figure 1C) . Also, in freshly isolated monocytes from human whole blood, ex vivo incubation with another GLP-1 receptor agonist, exendin-4, reduced the intensity of the oxidative burst ( Figure 1D) . Likewise, the mRNA expression of the Nox subunit Nox2 was strongly stimulated by LPS treatment ( Figure 1E ) and significantly inhibited by incubation of the cells with linagliptin or liraglutide in a dose-dependent manner. These data are in accordance with our previous observations that in vivo linagliptin and liraglutide therapy prevented the oxidative burst in whole blood from LPS-treated rats (Steven et al., 2015a) . In addition, several DPP-4 inhibitors suppressed the activation of monocytes and neutrophils, their adhesion to cultured endothelial cells and the infiltration of leukocytes to the vascular wall of LPS-treated rats (Kroller-Schon et al., 2012) . Effects of DPP-4 inhibition or treatment with GLP-1 receptor agonist on endotoxaemia-induced thrombocytopenia and pulmonary microvascular thrombosis LPS-induced endotoxaemia in wild-type mice led within 12 h to a severe fall in platelet count and an increase in pulmonary microvascular thrombus formation over time, which was negatively correlated with time after LPS injection (r = À0.8923; P < 0.05) (Figure 2A ). DPP-4-inhibtion by linagliptin and supplementation with the GLP-1 receptor agonist liraglutide or genetic knockout of DPP-4 (DPP-4 À/À ) prevented the fall in thrombocyte numbers. In endotoxaemic GLP-1r À/À mice, linagliptin or liraglutide treatment had no protective effect ( Figure 2B ). The activity of LDH, determined as a parameter of end organ damage due to microvascular thrombosis and tissue hypoxia, was markedly increased in septic animals and significantly reduced by linagliptin or liraglutide treatment ( Figure 2C ). Linagliptin and liraglutide treatment as well as DPP-4 deficiency largely prevented LPS-induced microvascular thrombus formation in lungs ( Figure 3A ). In contrast, linagliptin or liraglutide failed to improve pulmonary microvascular thrombosis in GLP-1r À/À mice, pointing towards an important role of GLP-1 receptor signalling in this phenomenon ( Figure 3A) . Fluorescent beads injected for imaging of microvascular thrombosis were detected by fluorescence microscopy of pulmonary sections. In lung sections of endotoxaemic wild-type mice, clusters of fluorescent beads were detectable, whereas in lungs of linagliptin-or liraglutide-treated and LPSchallenged animals, we detected almost no fluorescent cluster formation in pulmonary vessels. A similar protective effect was established in DPP-4 À/À mice. Interestingly, in animals lacking GLP-1 receptors, linagliptin or liraglutide treatment had no protective effect ( Figure 3B ). Fibrinogen staining co-localized with the fluorescence signal of fluorescent beads, indicating that fluorescent beads cluster formation was correlated with LPS-induced microthrombi formation ( Figure 3C ). Furthermore, this protein was detectable in human monocytes and, in higher concentrations, in human platelets ( Figure 4B ). In PRP of linagliptin-or liraglutide-treated animals, thrombin generation [endogenous thrombin potential (ETP)] triggered by TF was significantly reduced ( Figure 4C ). In contrast, thrombin generation in platelets from GLP-1 receptor deficient mice was significantly increased compared with that in platelets from control and DPP-4 À/À mice ( Figure 4D ). Additionally, aggregation of platelets from GLP-1r À/À mice was significantly increased in response to thrombin and ADP, compared with those from wild-type mice( Figure 4E ). Incubation of murine platelets with the GLP-1 receptor agonist exendin-4 induced a robust increase of VASP-Ser 157 phosphorylation, a marker of increased intracellular cAMP formation ( Figure 4F ). In isolated platelets from GLP-1r À/À mice, in vitro incubation with exendin-4 showed no increase of VASP phosphorylation at Ser 157 ( Figure 4G ).
DPP-4 inhibition
These results are compatible with an inhibitory effect of GLP-1 receptor agonists on platelet aggregation, which is mediated, at least in part, via the cAMP/PKA pathway.
In vitro experiments on human platelets revealed a dosedependent inhibitory effect of the GLP-1 receptor agonists, liraglutide and exendin-4, on platelet activity. Both agonists reduced maximal platelet aggregation in response to ADP ( Figure 5A ) and thrombin (Supporting Information Fig. S3A and B). Thrombin generation in human platelets in PRP in response to thrombin (peak of thrombin generation and ETP) was significantly reduced by GLP-1 receptor agonists ( Figure 5B and C and Supporting Information Fig. S3C and D). Next, PRP from different healthy volunteers was isolated and incubated with increasing concentrations of exendin-4. Levels of cAMP, measured by ELISA, increased dosedependently in response to this GLP-1 receptor agonist ( Figure 5D ). We also observed a dose-dependent increase of PKA-dependent phosphorylation of VASP-Ser 157 and phosphorylation of PKA substrate (Ser/Thr) in response to Figure 5F ).
DPP-4 inhibition and treatment with GLP-1 receptor agonist prevent LPS-induced endothelial dysfunction and vascular inflammation and improve survival of endotoxaemic mice
In the last set of experiments, we also confirmed our previous findings with a DPP-4 inhibitor and supplementation with a GLP-1 receptor agonist in rats and mice (Kroller-Schon et al., 2012; Steven et al., 2015a) , but this time by using a genetic approach, DPP-4 and GLP-1 receptor knockout mice. Recently, we reported on improved survival of endotoxaemic wild-type mice after linagliptin or liraglutide treatment (Steven et al., 2015a) . As expected for a GLP-1 receptor agonist, treatment of GLP-1r À/À mice with liraglutide 6 h post-LPS injection did not improve survival of endotoxaemic mice and untreated GLP-1r À/À mice showed increased mortality in response to the dose of LPS (Figure 6 ). However, DPP-4 inhibition by linagliptin significantly reduced mortality in GLP-1r À/À mice, emphasizing the previously suggested GLP-1 receptor-independent effects of DPP-4 inhibitors, due to the plethora of targets of DPP-4 (Steven et al., 2015a,b) . LPS treatment induced endothelial dysfunction as indicated by a reduced ACh-induced vasorelaxation, which was markedly improved by treatment with linagliptin or liraglutide and, as a new result, by DPP-4 knockout (Supporting Information Fig. S4A and B) . To assess whether the protective ; (E-G) *P < 0.05 versus Ctr.
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effect of DPP-4 inhibition related to an increase of GLP-1 levels and stimulation of downstream GLP-1 receptor signalling or to other mechanisms, we applied linagliptin or liraglutide to endotoxaemic GLP-1r À/À mice. These studies revealed that the protective effects of these two drugs were almost completely lost in the absence of the GLP-1 receptor, compared with those in wild-type mice (Supporting Information Fig. S4C ). As shown before (Ku et al., 2010; Dai et al., 2014) , LPS treatment increased aortic mRNA expression of P-selectin, VCAM-1 and IL-6, compared with control, and linagliptin or liraglutide treatment reduced expression of these genes significantly (Supporting Information Fig. S2B-D) .
Discussion
With the present studies, we describe a hitherto unknown mechanism of platelet inhibition by GLP-1, namely, a receptor/cAMP/PKA signalling pathway with potential important clinical implications for the treatment of septic shock. Both DPP-4 inhibition and treatment with GLP-1 receptor agonists were able to attenuate thrombin generation in PRP. In vivo, these interventions prevented endotoxaemiainduced endothelial dysfunction and also prevented DIC and microvascular thrombus formation. Previous studies have demonstrated that DPP-4 inhibitors such as linagliptin exhibit pleiotropic vasodilatory, antioxidant and anti-inflammatory properties that were clearly independent of its glucose-lowering properties (Kroller-Schon et al., 2012) . In animals with LPS-induced septic shock, linagliptin improved endothelial dysfunction and ameliorated vascular superoxide formation. Furthermore, expression of Nox subunits and leukocyte infiltration into the vasculature were reduced. Importantly, linagliptin was very effective in inhibiting the oxidative burst in isolated activated human neutrophils and it suppressed their adhesion to activated endothelial cells (Kroller-Schon et al., 2012) .
These findings have been extended by the demonstration that treatment with linagliptin and deletion of DPP-4 both improved survival of endotoxaemic mice. Likewise, we established that DPP-4 inhibition reduced iNOS-dependent 
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NO production and aortic expression of iNOS, ICAM-1, MCP-1, TNF-α, VCAM-1 and IL-6 and simultaneously improved vascular function. The beneficial effects were attenuated in AMP-activated kinase (ɑ1) knockout animals, suggesting that part of these beneficial effects were mediated by AMPK activity (Steven et al., 2015a) . In addition, bleeding time was ameliorated by DPP-4 inhibition and GLP-1 supplementation with GLP-1 receptor agonists in rats with sepsis, as a first evidence for a role of DPP-4/GLP-1 signalling in haemostasis, however, without providing any mechanistic explanation. Interestingly, all these beneficial effects seem to be independent of blood glucose-lowering effects of the antidiabetic drugs. Thus, blood glucose or HbA1c levels were not affected (not shown) in linagliptin-treated mice (Kroller-Schon et al., 2012) or in DPP4 À/À or GLP-1r
The present studies demonstrated that leukocyte-derived NO formation in whole blood (HbNO) and the expression of iNOS were increased in endotoxaemia and that they were normalized by linagliptin or liraglutide treatment in mice given LPS. The lack of effect of both treatments on HbNO formation in GLP-1r (Figure 6 ). This points towards GLP-1-independent immunomodulatory effects of DPP-4 inhibition. DPP-4 has also been described as an adenosine deaminase-binding protein and to regulate the subcellular localization and activity of this enzyme, which has known immunomodulatory functions (Kameoka et al., 1993; Martin et al., 1995) . Several other protein targets were described for DPP-4, including caveolin-1, kidney Na + / H + ion exchanger 3, thromboxane A 2 receptor, CXCR4, CXCL12 (SDF-1), and fibronectin (Zhong et al., 2013) , and most of them are involved in the regulation of inflammation and coagulation. Linagliptin and liraglutide also dose-dependently inhibited the mRNA expression of the ROS-generating enzyme Nox2 and generation of ROS in cultured monocytes (MonoMac-1 cells) and the latter parameter also in freshly isolated human monocytes. Recently, two groups have reported anti-atherosclerotic and anti-inflammatory effects of GLP-1 receptor agonists in mice, which contribute to the inhibition of NF-kB/p65 nuclear translocation by increased cAMP levels in macrophages (Arakawa et al., 2010; Matsubara et al., 2012) . Furthermore, a GLP-1 receptor agonist inhibited ox-LDL uptake through a PKA/CD36 pathway in macrophages (Dai et al., 2014) . PGI 2 and the stable analogue iloprost are known to increase intracellular cAMP and to reduce oxidative burst in canine monocytes (Gryglewski et al., 1987; Simpson et al., 1987) .
As expected, in GLP-1r À/À mice, the GLP-1 receptor agonist liraglutide showed no protective effect on endothelial (vascular) function, suggesting that the beneficial effects of liraglutide in endotoxaemia are mainly mediated by GLP-1 receptor signalling. A characteristic feature of septic shock, also determining to a large extent survival in these animals, is DIC. DIC is a pathological process characterized by the widespread activation of the clotting cascade that results in the formation of blood clots in small blood vessels throughout the body. This will compromise tissue blood flow and will cause multiple end organ failure. In addition, since the coagulation process consumes clotting factors and platelets, normal clotting is disturbed and severe bleeding can occur at various sites. Previously, we had demonstrated that DPP4 inhibition improved haemostasis in septic animals (tail bleeding time and activated partial thromboplastin time) (Steven et al., 2015a) , but it remained to be established whether DIC might be also beneficially influenced by treatment with a GLP-1 receptor agonist and by what mechanism.
To quantify microvascular thrombus formation as a consequence of DIC, we used in the present studies, imaging with fluorescent beads. This technique has established the distribution of fluorescent beads in healthy hairless mice by demonstrating that 2.5-μm-sized beads pass through the pulmonary circulation and accumulate in spleen or liver (Tokalov and Bachiller, 2012) . Our experiments revealed similar findings for lungs of non-endotoxaemic animals, whereas the fluorescence signal in lungs of mice challenged with LPS was markedly increased, These increases were diminished by treatment with GLP-1 receptor agonist or s.c. for 3 days) was started 6 h after induction of endotoxaemia. A total of 48 animals and 12 animals per group were used (*P < 0.05 versus B6 mice; #P < 0.05 versus GLP-1r À/À mice).
by DPP-4 inhibition (Figure 3) . By using fluorescence microscopy, we further detected the fluorescent beads in the pulmonary microcirculation and were able to co-localize them with fibrin deposits. Based on data obtained from the time course in endotoxaemic mice, platelet count and microvascular thrombosis are strongly correlated. Next, we tested murine or human platelets for the presence of GLP-1 receptors. Because the presence of the GLP-1 receptor on human platelets had not been evaluated at the time the study was performed, we isolated platelets from human and murine whole blood. GLP-1 receptor protein was identified by Western blot technique in human monocytes and, in higher concentrations, in murine and human platelets.
Importantly, inhibition of DPP-4 by linagliptin or treatment with the GLP-1 receptor agonist liraglutide markedly reduced the fall in platelet count and normalized LDH activity, used as a marker for end organ damage. These data provide a potential explanation for our previous results on reduced mortality in endotoxaemia, following treatment with linagliptin and liraglutide (Steven et al., 2015a) .
The DPP-4 inhibitor linagliptin contains a methylxanthine structure. Such compounds inhibit PDE, leading to increased intracellular cAMP levels, for example, in cultured human macrophages (Matsubara et al., 2012) . As cAMP has also potent anti-aggregatory effects in platelets, we hypothesized that increased cAMP formation and subsequent PKA activation may represent the anti-aggregatory mechanism (as with PGI 2 ) that underlies the response to DPP-4 inhibition. Indeed, further experiments revealed that exposure of human and murine platelets to the GLP-1receptor agonist, exendin-4, increased VASP phosphorylation at Ser 157 (a marker for PKA activity), an effect that was absent from platelets taken from GLP-1r À/À mice. Exendin-4 also increased platelet cAMP content and the phosphorylation of PKA substrate, all compatible with a GLP-1receptor-mediated activation of the cAMP/PKA pathway. Liraglutide and exendin-4 were tested head to head in most ex vivo assays to show that this is a class effect of these drugs. Thrombin generation in PRP of non-endotoxaemic liraglutide-treated animals was significantly reduced. Both the GLP-1 analogues tested in this study, liraglutide and exendin-4, showed strong inhibitory effects on human platelet activation. Likewise, thrombin generation was markedly increased in GLP-1r À/À mice. The high plasma protein binding affinity of liraglutide might be the reason that higher concentrations of the drug were needed in PRP to induce effects, similar to those of exendin-4 (Plum et al., 2013) . Nevertheless, the concentrations used here for the in vitro experiments were higher than those usually observed in plasma from diabetic patients, treated with clinical doses of linagliptin or liraglutide (Elbrond et al., 2002; Graefe-Mody et al., 2012) . Therefore, higher drug doses might be required to observe effects on platelet function in patients. Taken together, these results clearly demonstrate that GLP-1 receptor signalling via a cAMP/PKA pathway is a strong regulator of platelet activation, relevant for primary (aggregation) and secondary (thrombin formation) haemostasis, in mice and humans. Very recently, Cameron-Vendrig et al. (2016 demonstrated an inhibitory action of the GLP-1 receptor agonist exenatide on platelet aggregation ex vivo and thrombus formation in animals. In accord with our data, they were able to detect the presence of the GLP-1 receptor on platelets. Furthermore, they were able to link these beneficial effects to elevated cAMP levels and observed a loss of platelet inhibition by exenatide in GLP-1r À/À mice (Cameron-Vendrig et al., 2016) . Thus, our data support the findings of Cameron-Vendrigs et al. and demonstrate the effectiveness of GLP-1 to inhibit platelet activation via the cAMP/PKA pathway in the setting of DIC.
In conclusion, the present studies confirmed the presence of GLP-1 receptors in platelets. GLP-1 receptor signalling (mediated by a cAMP/PKA pathway) was shown to be a new and powerful therapeutic approach to improve vascular function and to reduce intravascular thrombus formation, DIC and survival in the setting of septic shock. The antiinflammatory and anti-thrombotic action of GLP-1 may represent a novel approach to improve prognosis of septic patients. However, clinical trials are needed to further evaluate the use of GLP-1 receptor agonists or DPP-4 inhibitors in this particular group of patients.
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http://dx.doi.org/10.1111/bph.13549 Figure S1 (A) Dipeptidyl peptidase-4 (DPP-4) activity was detected using a specific peptide substrate with a terminal coumarin derivative (H-Ala-Pro-7-amido-4-trifluoromethylcoumarin; Bachem, Bubendorf, Switzerland; final concentration in the assay, 100 μM) allowing quantification in a fluorescence microplate reader after cleavage by DPP-4. These analyses were performed at the Department of Cardio-Metabolic Diseases Research, Boehringer Ingelheim Pharma GmbH and Co. KG. (B) Expression of GLP-1 receptors was quantified by qRT-PCR. The data are mean ± SEM from 8 mice per group. *, P < 0.05 versus wild-type mice (B6). Figure S2 (A-D) qRT-PCR was used to determine mRNA expression levels of iNOS, P-selectin, vascular adhesion molecule-1 (VCAM-1) and IL-6 in aortic tissue. Aortic tissue of 4 mice per group (A-D) *, P < 0.05 versus wild-type mice (B6) and #, P < 0.05 versus B6 + LPS. Figure S3 (A) ADP-and (B) thrombin-induced platelet aggregation was measured in PRP from healthy humans. Effects of exendin-4 (A) and liraglutide (B) are shown. Representative aggregation curves are shown for liraglutide experiments. (C, D) Effects of liraglutide on thrombin-dependent thrombin generation was measured by calibrated automated thrombography (CAT) assay in PRP of human subjects. The data are mean ± SEM from 3-4 human samples. *, P < 0.05 versus untreated sample. Figure S4 (A-C) Endothelium-dependent (ACh) relaxation was determined by isometric tension studies in mouse aortic ring segments. In order to provide best overview to the reader, the same curves for B6 and B6 + LPS are presented in different figures (dashed lines). Panel C: green and purple groups were also treated with LPS. A total number of 12-37 aortic rings from at least 6 animals per group (A-C) was used. (A,B) *, P < 0.05 versus wild-type mice (B6); #, P < 0.05 versus B6 + LPS. (C) *, P < 0.05 versus GLP-1r À/À ; #, P < 0.05 versus GLP-1r À/À + LPS.
